Stock Financial Ratios, Dividends, Split History

KCG / KCG Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,352.62
Book Value ($M)1,347.31
Book Value / Share19.92
Price / Book1.00
NCAV / Share-56.92
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 67,192,000
Weighted Average Number Of Shares Outstanding Basic 84,405,000
Common Shares Outstanding2 0
Weighted Average Number Of Diluted Shares Outstanding 86,160,000
Common Shares Outstanding 66,444,989
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.14
Return on Assets (ROA)0.04
Return on Equity (ROE)0.18
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income255.70
Earnings Per Share Basic3.03
Earnings Per Share Diluted2.97
Cash Flow Statement (mra) ($M)
Cash From Operations119.55
Cash from Investing62.47
Cash from Financing62.47
Identifiers and Descriptors
Central Index Key (CIK)1569391
Related CUSIPS
48244B900 48244B950

Split History

Stock splits are used by KCG Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Thiel backs bitcoin trading platform startup

Billionaire Peter Thiel’s venture capital firm Founders Fund is backing a startup that aims to bring Wall Street electronic trading expertise to the bitcoin market, the Wall Street Journal reports. (65-0)

A Few Months Ago, I Said 'Buy' Virtu At $17, Now It's $37

2018-04-23 seekingalpha
Virtu Financial is a company that has demonstrated its algorithms can withstand different market environments and consistently deliver trading profit. (10-1)

Get Long Vol With Virtu Financial Going Into Q1 Earnings

2018-04-10 seekingalpha
A consistently profitable business model with the benefit of increased profitability during market uncertainty makes it an ideal hedge to diversify a portfolio. (10-0)

Are High-Frequency Trading Firms Good Or Bad For Investors?

2018-04-04 seekingalpha
On last Friday's "Behind the Markets" podcast, we had a great discussion focused on high-frequency trading (HFT) - a topic that generates emotional reactions among the investor community, with many HFT firms viewed as predators picking off retail and institutional investors alike. The trading ecosystem can be opaque and confusing, and we had a balanced discussion on elements that are good and bad for investors. (4-0)

CUSIP: 48244B100